Australia-based Agilex Biolabs is a contract research organization (CRO) providing bioanalytical services for researchers at early stages of clinical development, supporting clients in Asia, Europe and the US.
Per its services, the company focuses on bioanalysis for small molecules and biologics for pharmacokinetics, immunogenicity and biomarkers, utilizing two platforms that conduct liquid chromatography, mass spectrometry, and immunoassays.
The expansion will see Agilex’s facilities located in a biotech hub in Adelaide, South Australia grow by 30%, enabling the company to include a range of additional pharmacodynamics services in its offering.
According to the company, the Adelaide laboratory is the only FDA-inspected facility of its type in the region.
Agilex’s CEO, Jason Valentine, said that the facility employs more than 65 dedicated laboratory staff, working to support more than 80 clinical trials every year.
“This year we will analyze more than 60,000 samples for pharma and biotechs from the US, Europe and APAC,” said Valentine, adding that, to date, the company has supported hundreds of preclinical and clinical trials around the world.
Amid the ongoing coronavirus pandemic, the company announced that it will be offering virtual tours in the expanded laboratories.